Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecipioSTU:TGK 51 EV-to-FCF is 77.65 as of Jul. 15, 2026. GuruFocus rates STU:TGK with a GF Score™ of 51/100 and a GF Value™ of €2.26. The stock has 2 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Precipio ranks worse than 83.84% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Precipio's Enterprise Value is €37.19 Mil.
Precipio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €0.48 Mil. Therefore, Precipio's EV-to-FCF for today is 77.65.
The historical rank and industry rank for Precipio's EV-to-FCF or its related term are showing as below:
STU:TGK'
s EV-to-FCF Range Over the Past 10 Years
Min: -168.57 Med: -1.83 Max: 139.78
Current: 76.32
During the past 13 years, the highest EV-to-FCF of Precipio was 139.78. The lowest was -168.57. And the median was -1.83.
STU:TGK's EV-to-FCF is ranked worse than 83.84% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.47
vs STU:TGK: 76.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Precipio's share price for today is €4.96.
Precipio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.411.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Precipio EV-to-FCF Related Terms
Precipio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Precipio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Precipio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Precipio's EV-to-FCF falls into.
Precipio's current Enterprise Value is €37.19 Mil.
Precipio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precipio (STU:TGK) has a EV-to-FCF of 77.65 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Precipio and its competitors. According to the industry distribution chart, Precipio ranks #83 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 83.8%.
Is Precipio's EV-to-FCF too high?
Precipio's current EV-to-FCF is 77.65. The Medical Diagnostics & Research industry median EV-to-FCF is 25.47. Precipio's value of 77.65 is 204.9% above this industry median. Based on the distribution chart, Precipio ranks #83 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Precipio has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Precipio's EV-to-FCF compare to QUCY and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #83 out of 99 companies for EV-to-FCF. This places Precipio in the lower half of its industry. The industry median EV-to-FCF is 25.47. Precipio's value of 77.65 is 204.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 25.47, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precipio's current EV-to-FCF of 77.65 is 204.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Precipio and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 25.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precipio's current EV-to-FCF is 77.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Precipio (STU:TGK) has a current EV-to-FCF of 77.65. The stock's GF Value™ is €2.26, compared to a current price of €4.96 — trading 119.5% above its estimated fair value. The current EV-to-FCF is 77.65 and 204.9% above the Medical Diagnostics & Research industry median of 25.47. Precipio's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Precipio (STU:TGK), the current EV-to-FCF is 77.65 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (STU:TGK) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of €4.96 is trading 119.5% above its estimated GF Value™ of €2.26.
Key valuation signals for STU:TGK:
EV-to-FCF: 77.65
GF Value™: €2.26 vs. price of €4.96 (119.5% above fair value)
Industry Position: 204.9% above the Medical Diagnostics & Research median (#83 of 99)
No single metric tells the full story. See the STU:TGK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score
Get the complete analysis for STU:TGK
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:TGK has been successfully added to your 
